Case report: CNS tuberculoma in a patient with prior pulmonary tuberculosis
Abstract
Abstract Central nervous system (CNS) tuberculoma is a rare but severe form of tuberculosis (TB) that can mimic other neurological disorders and poses major diagnostic challenges, especially with drug resistance. We report a case of a woman in her 60s who developed CNS tuberculoma four years after completing anti-tuberculosis therapy (ATT) for pulmonary TB. She presented with progressive left-sided weakness, facial asymmetry, and dysphagia. MRI revealed a ring-enhancing lesion in the right caudate nucleus with a lipid-lactate peak on spectroscopy, consistent with tuberculoma. Drug susceptibility testing confirmed resistance to isoniazid and rifampicin, indicating multidrug-resistant TB (MDR-TB). A modified regimen with levofloxacin, ethionamide, and para-aminosalicylic acid led to neurological recovery. This case underscores the importance of considering CNS tuberculoma in patients with neurological deficits and prior TB, even after apparent cure. Early neuroimaging, drug resistance testing, and individualized therapy are vital to improving outcomes and reducing morbidity and mortality.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.